Page last updated: 2024-12-08
2,6-dimethyloctane-1,8-dioic acid
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
2,6-dimethyloctane-1,8-dioic acid: metabolite of phytanic acid; found in patients suffering from Refsum's disease [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 193373 |
| CHEBI ID | 180323 |
| SCHEMBL ID | 14360231 |
| MeSH ID | M0112984 |
Synonyms (12)
| Synonym |
|---|
| 2,6-dimethyl-1,8-octanedioic acid |
| CHEBI:180323 |
| 3269-74-7 |
| 2,6-dimethyloctanedioic acid |
| LMFA01170129 |
| bms-197564 |
| 2,6-dmoa |
| 2,6-dimethyloctane-1,8-dioic acid |
| octanedioic acid, 2,6-dimethyl- |
| bms 197564 |
| SCHEMBL14360231 |
| DTXSID00954377 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| medium-chain fatty acid | Any fatty acid with a chain length of between C6 and C12. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.74
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.74) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (20.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (20.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 3 (60.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||